SFIX

Stitch Fix reported a narrower-than-expected Q4 adjusted loss and revenue growth, with revenue per active client reaching a record $592. However, active client count declined 1.4%, and management expects a more challenging consumer environment and higher acquisition costs in fiscal 2027.

The company issued guidance reflecting expected revenue decline of 2.8% to potential growth of 0.9%, with significantly lower adjusted EBITDA projections. Analysts have downward trending estimates, resulting in a Zacks Rank #4 (Sell) rating.

Pomerantz LLP announced investigations into potential securities fraud and unlawful business practices at Stitch Fix, JinkoSolar, and America's Car-Mart. Stitch Fix's stock fell 21.63% following disappointing Q4 2026 earnings with declining active clients and net losses.

Pomerantz LLP announced investigations into securities fraud claims against SELLAS Life Sciences, JinkoSolar, and Stitch Fix. The investigation into SELLAS focuses on delayed release of phase 3 clinical trial results for Galinpepimut-S, which triggered an 13.15% stock price decline on August 28, 2026.

Pomerantz LLP announced investigations into potential securities fraud at Rent the Runway following the company's September 11, 2026 earnings report, which revealed a 3.8% year-over-year decline in active subscribers, disappointing Q3 guidance, and a dilutive capital raise. The stock fell 13.12% on the news. Similar investigations were initiated for JinkoSolar and Stitch Fix.

Pomerantz LLP announced investigations into potential securities fraud at Abeona Therapeutics following disclosure that only 4 of 5 ZEVASKYN treatments were recognized for revenue due to one batch lacking minimum sheet requirements. The stock fell 14.95% to $6.35 on August 13, 2026. Similar investigations were initiated for JinkoSolar and Stitch Fix.